Clavis Pharma

About Clavis Pharma

Clavis Pharma, founded in Oslo, Norway in 2001 by Carlos Roig, was a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's core strategy revolved around its proprietary Lipid Vector Technology (LVT) platform. This technology aimed to enhance well-established drug molecules by chemically binding them to specific unsaturated lipids, creating new chemical entities with potentially improved efficacy and reduced side effects.

The company's business model was centered on advancing its drug candidates through clinical trials to demonstrate proof of principle in humans. Upon achieving significant value and positive data, Clavis Pharma planned to seek strategic partnerships with larger pharmaceutical or biotech companies for late-stage clinical development and commercialization. The company engaged in multiple funding rounds to support its research and development activities, securing investments from firms like NeoMed, MVM, and Innovasjon Norge.

A key product in Clavis Pharma's pipeline was elacytarabine (CP-4055), a lipid-conjugated version of the anti-cancer drug cytarabine, developed for the treatment of leukemia. Another significant candidate was CP-4126, a lipid-conjugated form of gemcitabine, aimed at treating pancreatic and other solid tumors. In a notable milestone, Clavis Pharma entered into a major partnership with Clovis Oncology in 2009 for the development and commercialization of CP-4126. This agreement, initially valued at up to $380 million, granted Clovis Oncology rights in the Americas and Europe and was later expanded to include global rights, increasing the potential payments.

Despite the promising technology and substantial partnerships, the company faced significant setbacks. In 2012, Clovis Oncology halted the development of CP-4126 (then known as CO-101) after it failed to demonstrate improved survival in a late-stage pancreatic cancer trial. This was followed by the failure of its lead drug, elacytarabine, in a late-stage trial for leukemia in 2013. The successive failures of its two lead candidates, both based on the LVT platform, led the company to consider closing down or being sold, and it is now considered a deadpooled entity.